Viking Therapeutics (VKTX) Total Non-Current Liabilities (2014 - 2026)
Viking Therapeutics (VKTX) posted Total Non-Current Liabilities of $3.9 million for Q2 2026, up 1134.28% sequentially from $318000.0 in Q3 2025, and up 857.32% YoY from $410000.0 in Q2 2025.
Viking Therapeutics (VKTX) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Total Non-Current Liabilities for 12 years, with the latest figure at $3.9 million in Q2 2026.
- Quarterly Total Non-Current Liabilities rose 857.32% year-over-year to $3.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.9 million (up 857.32% YoY) and the FY2024 annual result came in at $630000.0, down 32.69% from the prior year.
- Total Non-Current Liabilities climbed to $3.9 million in Q2 2026 per VKTX's latest filing, from $318000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $3.9 million in Q2 2026 and troughed at $318000.0 in Q3 2025.
- A 5-year average of $1.1 million and a median of $977000.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities tumbled 57.88% in 2025, then surged 857.32% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $1.3 million in 2022, then retreated by 25.71% to $936000.0 in 2023, then plunged by 32.69% to $630000.0 in 2024, then sank by 49.52% to $318000.0 in 2025, then soared by 1134.28% to $3.9 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $3.9 million, $318000.0, and $410000.0 for Q2 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | 3.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.93 Mn |
| Sep 30, 2025 | 318,000.00 |
| Jun 30, 2025 | 410,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Dec 31, 2024 | 630,000.00 |
| Sep 30, 2024 | 755,000.00 |
| Jun 30, 2024 | 766,000.00 |
| Mar 31, 2024 | 852,000.00 |
| Dec 31, 2023 | 936,000.00 |
| Sep 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Dec 31, 2022 | 1.26 Mn |
| Sep 30, 2022 | 1.34 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 1.49 Mn |
| Dec 31, 2020 | 29,000.00 |
| Sep 30, 2020 | 115,000.00 |
| Jun 30, 2020 | 198,000.00 |
| Mar 31, 2020 | 279,000.00 |